| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802254001011 | 225400101 | HUMALOG INJ.SOL 100 U/ML BTX1VIALX10ML | 13.79 | 14.47 | 19.94 |
| 05/2018 | 2802254003022 | 225400302 | HUMALOG-CARTRIDGE INJ.SOL 100 U/ML BTX5 CARTR.X3ML | 23.97 | 25.14 | 34.64 |
| 05/2018 | 2802254007013 | 225400701 | HUMALOG-MIX 25 CARTRIDGE INJ.SUSP 100 U/ML CARTR.3ML BTx5ΦΥΣΙΓΓΙΑ/CARTR. HUMALOG MIX25 x 3 ML HUMALOG MIX25 X 3 ML | 25.26 | 26.50 | 36.52 |
| 05/2018 | 2802254011010 | 225401101 | HUMALOG-MIX 50 CARTRIDGE INJ.SUSP 100 U/ML CARTR.3ML BTx 5 ΦΥΣΙΓΓΙΑ/CARTR. HUMALOG MIX50 x 3ML HUMALOG MIX50 X 3ML | 24.95 | 26.17 | 36.06 |
| 05/2018 | 2802254018019 | 225401801 | HUMALOG (KWIKPEN) INJ.SOL 100 IU/ML BTx 5 PF PEN x 3ML (3,5MG/ML) (3,5MG/ML) | 28.46 | 29.85 | 41.14 |
| 05/2018 | 2802254019016 | 225401901 | HUMALOG (MIX 25 KWIKPEN) INJ.SUSP 100 U/ML BTx 5 PF PEN x 3ML (3,5MG/ML) (3,5MG/ML) | 29.12 | 30.54 | 42.08 |
| 05/2018 | 2802254020012 | 225402001 | HUMALOG (MIX 50 KWIKPEN) INJ.SUSP 100 U/ML BTx 5 PF PEN x 3ML (3,5MG/ML) (3,5MG/ML) | 29.12 | 30.54 | 42.08 |
| 05/2018 | 2802254022030 | 225402203 | HUMALOG KWIKPEN INJ.SOL 200 U/ML BTx5 PF.PEN x3ML (6,9mg/ML) | 56.47 | 59.24 | 75.36 |
For the treatment of Type 1 or 2 diabetes mellitus. To be used in conjunction with an intermediate or long-acting insulin except when used in a continuous insulin infusion pump.
Insulin lispro binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism. In humans, insulin is stored in the form of hexamers; however, only insulin monomers are able to interact with IR. Reversal of the proline and lysine residues at positions B28 and B29 of native insulin eliminates hydrophobic interactions and weakens some of the hydrogen bonds that contribute to the stability of the insulin dimers that comprise insulin hexamers. Hexamers of insulin lispro are produced in the presence of zinc and <i>m</i>-cresol. These weakly associated hexamers quickly dissociate upon subcutaneous injection and are absorbed as monomers through vascular endothelial cells. These properties give insulin lispro its fast-acting properties.
Inappropriately high dosages relative to food intake and/or energy expenditure may result in severe and sometimes prolonged and life-threatening hypoglycemia. Neurogenic (autonomic) signs and symptoms of hypoglycemia include trembling, palpitations, sweating, anxiety, hunger, nausea and tingling. Neuroglycopenic signs and symptoms of hypoglycemia include difficulty concentrating, lethargy/weakness, confusion, drowsiness, vision changes, difficulty speaking, headache, and dizziness. Mild hypoglycemia is characterized by the presence of autonomic symptoms. Moderate hypoglycemia is characterized by the presence of autonomic and neuroglycopenic symptoms. Individuals may become unconscious in severe cases of hypoglycemia. Rare cases of lipoatrophy or lipohypertrophy reactions have been observed.
Rapidly absorbed following subcutaneous administration. To be administer within 15 minutes before a meal.
1 hour
* 0.26 to 0.3 L/kg